CA Patent

CA2863002A1 — Processes for making hcv protease inhibitors

Assigned to AbbVie Ireland ULC · Expires 2013-07-18 · 13y expired

What this patent protects

Efficient processes for making HCV protease inhibitors are described. In one embodiment, the process uses novel idazolide derivatives of vinyl-ACCA.

USPTO Abstract

Efficient processes for making HCV protease inhibitors are described. In one embodiment, the process uses novel idazolide derivatives of vinyl-ACCA.

Drugs covered by this patent

Patent Metadata

Patent number
CA2863002A1
Jurisdiction
CA
Classification
—
Expires
2013-07-18
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.